13 days old

Director, Market Access (Rare Disease & I&I)

Pfizer
New York, NY 10007
Apply Now
Apply on the Company Site
**ROLE SUMMARY**

Successful global market access is fundamental to the achievement of Pfizer's commercial objectives in the evolving, complex pharmaceutical payer environment, which must begin in early development. The Rare Disease (RD) and Immunology and Inflammation (I&I) business units within Pfizer have a robust pipeline of products within various rare diseases in: hematology, cardiology, neuromuscular, metabolic and endocrine (RD), including several gene and cell therapy assets across these TAs, and medical dermatology, rheumatology, and gastroenterology (GI; I&I).



The Director, Market Access (Rare Disease & I&I), is responsible for development of high-quality market access and pricing strategies to ensure payer insights are included into the development plans of early pipeline assets, and business development assessments for national-level public payers and private commercial insurers. The MAx director will lead the development of strategies for four (4) TA areas across RD and I&I: three (3) in RD: hematology, neuromuscular, metabolic and in I&I GI. The colleague will also assess pipeline lifecycle management opportunities.



GMAx takes a global business-wide perspective and must adopt a leadership position on strategic questions with respect to the value, access and outcomes required of assets in development and be the "voice of the payer" to internal stakeholders. The director must have a high degree of expertise and employ a patient and payer-centric mindset to work closely in an aligned fashion with various partner and stakeholder groups and innovative approaches for RD and gene and cell therapies in development. This will ensure there is a single and coordinated view on strategy to provide timely delivery of PHI outputs to inform key business decisions. Lastly, the Director must be able to design, develop and implement an integrated approach to all aspects of the payer value proposition from early development through phase III and across geographies (such as US, EU, Asia) for RD & I&I TAs described above.



**ROLE RESPONSIBILITIES**



+ Partner with the early asset teams to deliver clear recommendations and insights relating to access strategies, pricing and reimbursement scenarios, payer evidence generation requirements, and payer value propositions

+ Qualitative and Quantitative Pricing Research

+ Strong knowledge of US and EU-5 required other geographies preferred

+ Gather insights from U.S. payers on potential path forward in early assets

+ Identify patient and payer challenges, analyze and prioritize critical evidence requirements and assesses implications of potentially not generating appropriate evidence to address these challenges and meeting certain patient or payer needs to facilitate patient access

+ Interpret trends shaping the future price and access landscape to provide input into development decisions;

+ Recognition and ability to pressure test and challenge assumptions on hurdles in pricing, access and affordability including annuity and lump sum payment based approaches, product guarantees, gross-to-net calculations, willingness-to-pay assessments (or others) and access challenges

+ Propose solutions to overcome challenges toward revenue forecasts;

+ Eliminates or minimizes barriers to progress, engages senior leadership, when appropriate, regarding marketplace trends, business opportunities & threats, competitive information, and recommendations

+ Strong understanding and experience of working within the global payer environment and drivers for reimbursement, value-based access, and how to integrate into drug development, (MAx/HEOR/PROs in Clinical trials) and commercial strategies.

+ Provide PHI viewpoint on internal assessments or Business Development opportunities across RD & I&I

+ Provide strategic guidance in partnership with BD teams on optimal pricing and access strategies for BD deals;

+ Conduct rapid payer research to assess pricing potential of products across RD or I&I;



+ Partner with PHI members and cross-functional teams from early development to Phase III RD & I&I assets; bring creative solutions while employing cutting-edge methodologies and innovative ideas which could be scaled.

+ Develop comprehensive view of product opportunities and pricing/access scenarios for US, EU and other regions as applicable

+ Partner to conduct price implications of cadence/launch sequencing for Ex-U.S. markets:

+ Work efficiently and collaboratively in a highly matrixed environment



+ Execute projects as per Operating Plans or newly identified priorities and manage pipeline budget for those projects.



**BASIC QUALIFICATIONS**

Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.



+ Bachelor's degree required. Preferred: Advanced degree (MS, MPH, PhD, PharmD, MD) in a healthcare, business or economic field, and/or fellowship training.

+ Minimum of 5-7 years of experience in the healthcare environment, preferably pharmaceutical industry or related consulting services, sufficient to have developed a deep understanding of the global market access environment

+ Minimum of 4 years in GMAx, health outcomes, marketing, finance or related experience with proven track record in leading development and managing execution of strategy

+ Demonstrated pharmaceutical business leadership, including experience in strategy development and interaction with customers

+ Demonstrate expertise in payer regulation and priorities and ability to determine implications for product pricing and access strategies;

+ Experience with or exposure to payers (open to any combinations of):

+ US payers: Commercial, Medicare (inc. Part D), State & Managed Medicaid, and/or Employer Groups

+ Globally: experience with HTA organizations such as NICE, G-Ba, HAS, CADTH, PBAC

+ Strong customer-orientation and proven ability to operate effectively in the matrix environment

+ Knowledge and understanding of PROs for payers (e.g. EQ-5D-5L), health economics and associated skills

+ Familiarity with strategic and operating planning processes

+ Demonstrated ability to manage multiple projects organizational and workload via strong planning skills

+ Excellent oral and written English communication skills required



**PREFERRED QUALIFICATIONS**



+ RD, Gene and cell therapy and/or I&I experience preferred

+ Understanding of gene and cell therapy reimbursement policies and procedures

+ Strong interpersonal skills and active listening.

+ Proven ability to develop strong partnerships across functions.

+ Executive presence and ability to interact effectively with all levels of the organization.

+ Outstanding writing and presentation skills.

+ Ability to work under pressure, to take accountability for business challenges, thinks strategically and tackles complex problems.

+ Intellectual curiosity and ability to spot trends/ patterns.

+ Strong customer-orientation; an ability to see issues from the point of view of others.

+ Ability to work successfully and cooperatively with colleagues across multiple cultures and time-zones.

+ An "execution mindset" focused on getting things done



**Other Job Details:**

Last Date to Apply for Job: January 31st, 2021

Additional Location Information: New York, NY; Collegeville, PA

\#LI-PFE



**Sunshine Act**

Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws and implementing regulations. These laws and regulations require Pfizer to provide government agencies with information such as a health care provider's name, address and the type of payments or other value received, generally for public disclosure. Subject to further legal review and statutory or regulatory clarification, which Pfizer intends to pursue, reimbursement of recruiting expenses for licensed physicians may constitute a reportable transfer of value under the federal transparency law commonly known as the Sunshine Act. Therefore, if you are a licensed physician who incurs recruiting expenses as a result of interviewing with Pfizer that we pay or reimburse, your name, address and the amount of payments made currently will be reported to the government. If you have questions regarding this matter, please do not hesitate to contact your Talent Acquisition representative.



**EEO & Employment Eligibility**

Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Pfizer is an E-Verify employer.



Market Access



\#LI-PFE
Posted: 2021-01-11 Expires: 2021-02-11
Sponsored by:
ADP Logo

Before you go...

Our free job seeker tools include alerts for new jobs, saving your favorites, optimized job matching, and more! Just enter your email below.

Share this job:

Director, Market Access (Rare Disease & I&I)

Pfizer
New York, NY 10007

Join us to start saving your Favorite Jobs!

Sign In Create Account
Powered ByCareerCast